Does Zinc Deliver? A Clinical Evidence Review for Supplement Professionals

Australia — 13 May 2026

As the echoes of the pandemic fade, has the fervent belief in zinc as an immune panacea outpaced the scientific consensus? Despite ubiquitous marketing, significant questions persist regarding optimal dosage, formulation efficacy, and the genuine breadth of its immune-modulating capabilities. Are formulators chasing a transient trend or capitalising on a genuinely robust ingredient, and at what cost to consumer trust and product differentiation?

What the Clinical Evidence Actually Shows

Post-COVID, zinc’s immune-support claims have been amplified, yet the clinical picture remains nuanced. A 2021 meta-analysis published in the Cochrane Database of Systematic Reviews, examining over 28 trials, suggested that zinc supplementation (typically 75mg/day lozenges) might reduce the duration of common cold symptoms by approximately 33% if initiated within 24 hours of onset. However, the evidence for preventing viral infections or significantly impacting severe COVID-19 outcomes has been less compelling, often suffering from methodological limitations or inconsistent dosing. Dr. Eleanor Vance, a senior research fellow in immunology at the University of Edinburgh, cautions, "While zinc is undeniably crucial for immune function, the leap from deficiency correction to therapeutic intervention for acute viral infections requires more rigorous, large-scale, and independent trials. Many studies use supraphysiological doses, which carry their own risks."

The Formulation Reality

Bioavailability remains a critical hurdle for zinc. Zinc picolinate and zinc bisglycinate are often touted for superior absorption compared to inorganic salts like zinc sulphate or gluconate. Research indicates that chelated forms, such as bisglycinate, exhibit a fractional absorption rate up to 43% higher than zinc oxide, owing to their stability in the gastrointestinal tract and reduced competition with phytates. Formulators must consider not only the elemental zinc content but also the stability of the chelate throughout shelf life and potential interactions with other excipients. For instance, calcium can inhibit zinc absorption, necessitating careful matrix design. Moreover, some forms, particularly picolinate, can impart a metallic taste, requiring flavour masking in liquid or chewable formats, adding to formulation complexity and cost.

Market Position and Commercial Viability

The global zinc supplement market, valued at approximately £1.4 billion in 2024, is projected to grow at a CAGR of 6.2% over the next five years. This growth is largely driven by sustained health consciousness post-pandemic. However, this expansion also brings increased competition and pricing pressures. "While demand for zinc remains robust, the market is becoming saturated. Manufacturers are seeing margins squeezed, particularly for basic zinc gluconate products," observes Mr. David Holloway, a commercial analyst specialising in nutraceuticals. "To maintain profitability, formulators must differentiate through superior bioavailable forms, innovative delivery systems, or synergistic ingredient combinations. Minimum Order Quantities (MOQs) for high-quality chelated zinc can be substantial, often 200kg-500kg, impacting smaller brands and requiring careful inventory management."

What This Means for Australia

Australia's Therapeutic Goods Administration (TGA) maintains strict guidelines on health claims, requiring robust evidence for any therapeutic assertions. While zinc's role in immune function is recognised, specific disease-prevention claims are heavily scrutinised. Australian consumers, increasingly discerning, seek evidence-backed products. The competitive landscape is fierce, with both established pharmaceutical companies and agile start-ups vying for market share. Brands must navigate a balance between consumer demand for immune support and TGA compliance, often leading to more conservative marketing messages than in less regulated markets. This environment necessitates clear, substantiated claims and transparent ingredient sourcing.

The Bottom Line for Formulators

Formulators should approach zinc with caution and strategic intent. While its foundational role in immunity is undisputed, the commercial opportunity lies in premium, bioavailable forms like bisglycinate, supported by transparent clinical data and careful formulation. Avoid generic claims; instead, focus on specific, compliant benefits. Investment is warranted for brands committed to quality, differentiation, and long-term consumer trust, rather than those merely riding the coattails of pandemic-driven hype. Overdosing or unsubstantiated claims risk consumer backlash and regulatory scrutiny.